carbamazepine has been researched along with Aging in 47 studies
Carbamazepine: A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties.
carbamazepine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant.
Aging: The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the relative tolerability and efficacy of two newer antiepileptic drugs, lamotrigine (LTG) and gabapentin (GBP), as compared to carbamazepine (CBZ) in older patients with epilepsy." | 9.11 | New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. ( Boardman, KD; Carter, GS; Collins, JF; Felicetta, J; Frederick, T; Marks, W; Pryor, F; Ramsay, RE; Rowan, AJ; Spitz, M; Tomyanovich, ML; Towne, A; Uthman, BM, 2005) |
| "The authors examined sodium concentrations from 97 oxcarbazepine-treated (OXC) and 451 carbamazepine-treated (CBZ) patients with epilepsy using cross-section and follow-up studies." | 7.73 | Hyponatremia from oxcarbazepine and carbamazepine. ( Dong, X; Leppik, IE; Rarick, J; White, J, 2005) |
| "The effect of aging on carbamazepine (CBZ) plasma level/dose ratio was evaluated retrospectively in 15 children who were receiving CBZ monotherapy and who were followed up for at least 3 years." | 7.68 | A within-subject analysis of carbamazepine disposition related to development in children with epilepsy. ( Albani, F; Baruzzi, A; Contin, M; Riva, R, 1992) |
| "Immature rats are more susceptible to clonic seizures induced by aminooxyacetic acid (AOAA) than mature and senile rats." | 7.68 | Age dependency of the susceptibility of rats to aminooxyacetic acid seizures. ( Cavalheiro, EA; Dziki, M; Kleinrok, Z; Parada, J; Turski, W, 1992) |
| "To determine the relative tolerability and efficacy of two newer antiepileptic drugs, lamotrigine (LTG) and gabapentin (GBP), as compared to carbamazepine (CBZ) in older patients with epilepsy." | 5.11 | New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. ( Boardman, KD; Carter, GS; Collins, JF; Felicetta, J; Frederick, T; Marks, W; Pryor, F; Ramsay, RE; Rowan, AJ; Spitz, M; Tomyanovich, ML; Towne, A; Uthman, BM, 2005) |
| "Subjects were 85 men with localization-related epilepsy (25 on carbamazepine [CBZ], 25 on phenytoin [PHT], 25 on lamotrigine [LTG], and 10 untreated for at least 6 months [no AED]) and 25 controls." | 5.11 | Differential effects of antiepileptic drugs on sexual function and hormones in men with epilepsy. ( Bromfield, EB; Drislane, FW; Dworetzky, BA; Farina, EL; Frye, CA; Herzog, AG; Pennell, PB; Schomer, DL, 2005) |
| "The aim of the present study was to build population pharmacokinetic models for the clearance of carbamazepine (CBZ) in two separate populations of Serbian patients with epilepsy, children and adults." | 3.77 | Factors influencing carbamazepine pharmacokinetics in children and adults: population pharmacokinetic analysis. ( Jankovic, SM; Milovanovic, JR, 2011) |
| "To assess the influence of aging on the pharmacokinetics of phenobarbital (PB) at steady state in patients receiving long-term therapy." | 3.73 | Phenobarbital pharmacokinetics in old age: a case-matched evaluation based on therapeutic drug monitoring data. ( Battino, D; Croci, D; Mamoli, D; Messina, S; Perucca, E; Ratti, S, 2005) |
| "The authors examined sodium concentrations from 97 oxcarbazepine-treated (OXC) and 451 carbamazepine-treated (CBZ) patients with epilepsy using cross-section and follow-up studies." | 3.73 | Hyponatremia from oxcarbazepine and carbamazepine. ( Dong, X; Leppik, IE; Rarick, J; White, J, 2005) |
| " The multiple peak approach has been used to evaluate the effect of age, total body weight, dose, gender and comedication (carbamazepine-induced change) on population estimates of valproic acid relative clearance." | 3.69 | Detection of carbamazepine-induced changes in valproic acid relative clearance in man by simple pharmacokinetic screening. ( Aoyama, T; Higuchi, S; Honda, T; Ohdo, S; Yukawa, E, 1997) |
| "Carbamazepine (CBZ) used in the treatment of epilepsy, is metabolized in man to an active metabolite: carbamazepine 10-11 epoxide (CBZ-E)." | 3.68 | Distribution of carbamazepine and its epoxide in blood compartments in adolescent and adult epileptic patients. ( Bonneton, J; Genton, P; Mesdjian, E, 1992) |
| "The effect of aging on carbamazepine (CBZ) plasma level/dose ratio was evaluated retrospectively in 15 children who were receiving CBZ monotherapy and who were followed up for at least 3 years." | 3.68 | A within-subject analysis of carbamazepine disposition related to development in children with epilepsy. ( Albani, F; Baruzzi, A; Contin, M; Riva, R, 1992) |
| "Immature rats are more susceptible to clonic seizures induced by aminooxyacetic acid (AOAA) than mature and senile rats." | 3.68 | Age dependency of the susceptibility of rats to aminooxyacetic acid seizures. ( Cavalheiro, EA; Dziki, M; Kleinrok, Z; Parada, J; Turski, W, 1992) |
| "Plasma carbamazepine (CBZ) and carbamazepine-10,11-epoxide (CBZ-E) concentrations were measured in 160 epileptic patients in order to determine the effect of factors such as age, daily dosing schedule, formulation, and combination with other antiepileptic drugs on these concentrations in relation to the daily dose." | 2.68 | Factors influencing plasma concentrations of carbamazepine and carbamazepine-10,11-epoxide in epileptic children and adults. ( Bonato, PS; Campos, GM; Lanchote, VL; Rodrigues, I, 1995) |
| " The absorption rate and fraction are very much dependent on the pharmaceutical preparation, and changes of brand may alter the plasma level of phenytoin in spite of unaltered dose." | 2.35 | Clinical pharmacokinetics of anticonvulsants. ( Dam, M; Hvidberg, EF, 1976) |
| "To evaluate the relationship between serum concentrations of mono-hydroxy-carbazepine (MHD), the main metabolite of oxcarbazepine (OXC), and the occurrence of adverse effects (AE) in a large group of patients on OXC monotherapy." | 1.42 | Relationship between mono-hydroxy-carbazepine serum concentrations and adverse effects in patients on oxcarbazepine monotherapy. ( May, TW; Sattler, A; Schaefer, M, 2015) |
| " Age was a significant factor contributing to pharmacokinetic variability in individuals using LTG, OXC, and CBZ with increasing clearance as a function of bioavailability (Cl/F) over age 18, a maximum Cl/F at 33years (CBZ) and 36 years (LTG and OXC), and a gradual decrease of Cl/F towards older age." | 1.39 | The impact of age on lamotrigine and oxcarbazepine kinetics: a historical cohort study. ( Lindhout, D; Sander, JW; Wegner, I; Wilhelm, AJ, 2013) |
| "Fourteen patients developed seizures during that period and 25 did not." | 1.37 | Risk factors for late-onset seizures related to cerebral contusions in adults with a moderate traumatic brain injury. ( De Reuck, J, 2011) |
| "Epilepsy was confirmed in 58 cases." | 1.37 | [Epilepsy in elderly]. ( Kotov, AS; Rudakova, IG, 2011) |
| " Preliminary results from 60 patients on PHT therapy (41 elderly, mean age 76 years; 19 younger adults, mean age 41 years) indicate that PHT bioavailability did not differ between the two age groups; however, absorption and elimination half-lives were more variable in the elderly patients." | 1.34 | Factors affecting antiepileptic drug pharmacokinetics in community-dwelling elderly. ( Birnbaum, AK; Cloyd, JC; Marino, S, 2007) |
| " Our results showed that age-related influences in CBZ pharmacokinetics in elderly patients should be considered in the optimal planning of CBZ dosage regimens." | 1.33 | Population pharmacokinetic modelling of carbamazepine in epileptic elderly patients: implications for dosage. ( Belousov, YB; Bondareva, IB; Guekht, AB; Gusev, EI; Jelliffe, RW; Melikyan, EG, 2006) |
| "2 years, 1,594 (31%) had at least one interacting drug combination according to the Swedish National Formulary." | 1.29 | Potential drug--drug interactions in 5,125 mostly elderly out-patients in Gothenburg, Sweden. ( Bergendal, L; Friberg, A; Schaffrath, A, 1995) |
| "Oxcarbazepine was administered as a single dose of either 300 mg (men) or 600 mg (women), followed by multiple-dose (300 mg) administration twice a day for 7 days (men) or 6 days (women)." | 1.28 | The influence of age on the pharmacokinetics of the antiepileptic agent oxcarbazepine. ( de Bruin, H; Eve, MD; Hulsman, JA; Jensen, PK; Jonkman, JH; Oosterhuis, B; Richens, A; van Heiningen, PN, 1991) |
| " These findings should therefore be considered when defining dosage regimens or interpreting serum drug concentrations." | 1.28 | Analysis of the factors influencing anti-epileptic drug concentrations--valproic acid. ( Aoyama, T; Higuchi, S; Hirata, K; Ieiri, I; Yamada, H, 1990) |
| " In all cases, data on plasma levels were subjected to pharmacokinetic analyses." | 1.26 | Carbamazepine pharmacokinetics in young, adult and pregnant rats. Relation to pharmacological effects. ( Assael, BM; Bossi, L; Garattini, S; Gerna, M; Gomeni, R; Morselli, PL, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (27.66) | 18.7374 |
| 1990's | 17 (36.17) | 18.2507 |
| 2000's | 10 (21.28) | 29.6817 |
| 2010's | 6 (12.77) | 24.3611 |
| 2020's | 1 (2.13) | 2.80 |
| Authors | Studies |
|---|---|
| Fox, J | 1 |
| Ajinkya, S | 1 |
| Lekoubou, A | 1 |
| Wegner, I | 1 |
| Wilhelm, AJ | 1 |
| Sander, JW | 1 |
| Lindhout, D | 1 |
| Kutsuno, Y | 1 |
| Hirashima, R | 1 |
| Sakamoto, M | 1 |
| Ushikubo, H | 1 |
| Michimae, H | 1 |
| Itoh, T | 1 |
| Tukey, RH | 1 |
| Fujiwara, R | 1 |
| Sattler, A | 1 |
| Schaefer, M | 1 |
| May, TW | 1 |
| De Reuck, J | 1 |
| Milovanovic, JR | 1 |
| Jankovic, SM | 1 |
| Kotov, AS | 1 |
| Rudakova, IG | 1 |
| Dubois, CM | 1 |
| Zesiger, P | 1 |
| Perez, ER | 1 |
| Ingvar, MM | 1 |
| Deonna, T | 1 |
| Messina, S | 1 |
| Battino, D | 2 |
| Croci, D | 2 |
| Mamoli, D | 1 |
| Ratti, S | 1 |
| Perucca, E | 1 |
| Armijo, JA | 1 |
| Vega-Gil, N | 1 |
| Shushtarian, M | 1 |
| Adín, J | 1 |
| Herranz, JL | 1 |
| Rowan, AJ | 1 |
| Ramsay, RE | 1 |
| Collins, JF | 1 |
| Pryor, F | 1 |
| Boardman, KD | 1 |
| Uthman, BM | 1 |
| Spitz, M | 1 |
| Frederick, T | 1 |
| Towne, A | 1 |
| Carter, GS | 1 |
| Marks, W | 1 |
| Felicetta, J | 1 |
| Tomyanovich, ML | 1 |
| Herzog, AG | 1 |
| Drislane, FW | 1 |
| Schomer, DL | 1 |
| Pennell, PB | 1 |
| Bromfield, EB | 1 |
| Dworetzky, BA | 1 |
| Farina, EL | 1 |
| Frye, CA | 1 |
| Dong, X | 1 |
| Leppik, IE | 1 |
| White, J | 1 |
| Rarick, J | 1 |
| Bondareva, IB | 1 |
| Jelliffe, RW | 1 |
| Gusev, EI | 1 |
| Guekht, AB | 1 |
| Melikyan, EG | 1 |
| Belousov, YB | 1 |
| Cloyd, JC | 1 |
| Marino, S | 1 |
| Birnbaum, AK | 1 |
| Kalff, R | 1 |
| Houtkooper, MA | 1 |
| Meyer, JW | 1 |
| Goedhart, DM | 1 |
| Augusteijn, R | 1 |
| Meinardi, H | 1 |
| Morselli, PL | 2 |
| Franco-Morselli, R | 1 |
| Mares, P | 4 |
| Hlavatá, J | 1 |
| Lisková, K | 1 |
| Mudrochová, M | 1 |
| Kumps, A | 1 |
| Mardens, Y | 1 |
| Bossi, L | 2 |
| Franceschetti, S | 1 |
| Gomeni, C | 1 |
| Moise, A | 1 |
| Vitali, A | 1 |
| McKauge, L | 1 |
| Tyrer, JH | 1 |
| Eadie, MJ | 1 |
| van Boxtel, CJ | 1 |
| Rane, A | 2 |
| Brown, RD | 1 |
| Wilson, JT | 2 |
| Lanchote, VL | 1 |
| Bonato, PS | 1 |
| Campos, GM | 1 |
| Rodrigues, I | 1 |
| Liu, H | 2 |
| Delgado, MR | 2 |
| Temin, PA | 1 |
| Nikanorova, MIu | 1 |
| Plotnikova, IV | 1 |
| Seidl, J | 1 |
| Nováková, J | 1 |
| Bergendal, L | 1 |
| Friberg, A | 1 |
| Schaffrath, A | 1 |
| Gillham, R | 1 |
| Baker, G | 1 |
| Thompson, P | 1 |
| Birbeck, K | 1 |
| McGuire, A | 1 |
| Tomlinson, L | 1 |
| Eckersley, L | 1 |
| Silveira, C | 1 |
| Brown, S | 1 |
| Naganuma, Y | 1 |
| Konishi, T | 2 |
| Hongou, K | 2 |
| Okada, T | 1 |
| Tohyama, J | 1 |
| Uchiyama, M | 1 |
| Yukawa, E | 1 |
| Honda, T | 1 |
| Ohdo, S | 1 |
| Higuchi, S | 3 |
| Aoyama, T | 3 |
| Matsuzawa, J | 1 |
| Murakami, M | 1 |
| Yamatani, M | 1 |
| Yagi, S | 1 |
| Eravci, M | 1 |
| Pinna, G | 1 |
| Meinhold, H | 1 |
| Baumgartner, A | 1 |
| Pauwels, O | 1 |
| Hvidberg, EF | 1 |
| Dam, M | 1 |
| Assael, BM | 1 |
| Garattini, S | 1 |
| Gerna, M | 1 |
| Gomeni, R | 1 |
| Bonneton, J | 1 |
| Genton, P | 1 |
| Mesdjian, E | 1 |
| Albani, F | 1 |
| Riva, R | 1 |
| Contin, M | 1 |
| Baruzzi, A | 1 |
| Turski, W | 1 |
| Dziki, M | 1 |
| Parada, J | 1 |
| Kleinrok, Z | 1 |
| Cavalheiro, EA | 1 |
| van Heiningen, PN | 1 |
| Eve, MD | 1 |
| Oosterhuis, B | 1 |
| Jonkman, JH | 1 |
| de Bruin, H | 1 |
| Hulsman, JA | 1 |
| Richens, A | 1 |
| Jensen, PK | 1 |
| Suzuki, Y | 1 |
| Cox, S | 1 |
| Hayes, J | 1 |
| Walson, PD | 1 |
| Ichikou, N | 1 |
| Ieiri, I | 2 |
| Hirata, K | 2 |
| Yamada, H | 2 |
| Hlavatá-Nováková, J | 1 |
| Velísek, L | 1 |
| Roztocilová, L | 1 |
| Kubová, H | 1 |
| Hockings, N | 1 |
| Pall, A | 1 |
| Moody, J | 1 |
| Davidson, AV | 1 |
| Davidson, DL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicentre, Double-blind, Randomized, Phase IV Clinical Trial Comparing the Safety, Tolerability and Efficacy of Levetiracetam Versus Lamotrigine and Carbamazepine in the Oral Antiepileptic Therapy of Newly Diagnosed Elderly Patients With Focal Epileps[NCT00438451] | Phase 4 | 361 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00438451)
Timeframe: 58 weeks
| Intervention | proportion of participants (Mean) |
|---|---|
| Levetiracetam | 0.61 |
| Carbamazepine | 0.46 |
| Lamotrigine | 0.56 |
Percentage of patients experiencing no seizures until week 58 (Visit 6) and did not discontinue the study until week 58. (NCT00438451)
Timeframe: week 58
| Intervention | percentage of participants (Number) |
|---|---|
| Levetiracetam | 43 |
| Carbamazepine | 33 |
| Lamotrigine | 38 |
Percentage of patients experiencing no seizures until week 30 (Visit 4) and did not discontinue the study until week 30. (NCT00438451)
Timeframe: Week 30
| Intervention | percentage of participants (Number) |
|---|---|
| Levetiracetam | 48 |
| Carbamazepine | 39 |
| Lamotrigine | 49 |
(NCT00438451)
Timeframe: 52 weeks
| Intervention | proportion of seizure-free days (Number) |
|---|---|
| Levetiracetam | 0.99 |
| Carbamazepine | 0.99 |
| Lamotrigine | 0.99 |
EPITrack-Score shows the performance of attention and executive functions. Higher values indicate a better performance. The results of EPITrack Score ranges between 7 and 45. (NCT00438451)
Timeframe: week 58
| Intervention | units on a scale (Mean) |
|---|---|
| Levetiracetam | 26.0 |
| Carbamazepine | 26.0 |
| Lamotrigine | 25.4 |
"Seizure frequency was assessed by investigators in the CRF at the Visits V3, V4, V5 and V6.~The absolute seizure frequency during the maintenance phase was defined as the sum of those entries." (NCT00438451)
Timeframe: over 52 weeks
| Intervention | number of seizures (Number) |
|---|---|
| Levetiracetam | 168 |
| Carbamazepine | 131 |
| Lamotrigine | 130 |
(NCT00438451)
Timeframe: over the whole duration of 58 weeks
| Intervention | days (Median) |
|---|---|
| Levetiracetam | NA |
| Carbamazepine | NA |
| Lamotrigine | NA |
number of days between randomization and premature discontinuation of the study (NCT00438451)
Timeframe: 58 weeks
| Intervention | days (Median) |
|---|---|
| Levetiracetam | NA |
| Carbamazepine | 265 |
| Lamotrigine | NA |
"The PNS is a 15-item scale. Each item can be scored from 1 to 9. There are a total score (includes all items, range:15 to 135) and two subscores: The cognitive toxicity subscore (10 items: Energy Level, Memory, Interest, Concentration, Forgetfulness, Sleepliness, Moodiness, Alertness, Attention Span, Motivation, range:10 to 90) and the somatomoto subscore (5 items: Vision, Walking, Coordination, Tremor, Speech, range:5-45). The score is calculated by taking the mean of all non-missing values times the number of items.~Lower values indicate better quality of life." (NCT00438451)
Timeframe: at week 58
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Cognitive toxicity subscore | Somatomotor subscore | Total Score | |
| Carbamazepine | 27.3 | 11.4 | 38.7 |
| Lamotrigine | 23.7 | 10.8 | 34.5 |
| Levetiracetam | 22.2 | 10.5 | 32.7 |
The QOLIE-31 is a 31 item score that measures the quality of life in epilepsy (each item with a range of 0 to 100). There are 7 sub-scores seizure worry (items 11,21,22,23,25), overall quality of life (items 1,14), emotional well-being (items 3,4,5,7,9), energy/fatigue (items 2,6,8,10), cognitive functioning (items 12,15,16,17,18,26), medication effects (items 24,29,30) and social functioning (13,19,20,27,28). These scores were combined to a total score by Total score = seizure worry*0.08 + overall quality of life*0.14 + emotional well-being*0.15 + energy/fatigue*0.12 + cognitive functioning*0.27 + medication effects*0.03 + social functioning*0.21 For all scores, higher values indicate better quality of life. Each score has a possible range from 0 to 100. (NCT00438451)
Timeframe: 58 weeks, final visit
| Intervention | units on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Seizure worry | Overall quality of life | Emotional well-being | Energy/fatigue | Cognitive functioning | Medication effects | Social functioning | Total Score | Health Scale | |
| Carbamazepine | 75.4 | 65.0 | 69.8 | 54.5 | 68.9 | 70.6 | 76.3 | 68.9 | 65.7 |
| Lamotrigine | 75.0 | 67.1 | 67.4 | 59.8 | 68.0 | 72.6 | 76.7 | 69.1 | 67.5 |
| Levetiracetam | 85.1 | 67.2 | 72.0 | 60.8 | 75.1 | 77.6 | 81.1 | 73.9 | 69.5 |
"Evaluation of current testing at V6:~≥29 score points: Inconspicuous; 26 to 28 score points: Borderline;~≤25 score points: Impaired" (NCT00438451)
Timeframe: 58 weeks
| Intervention | participants (Number) | ||
|---|---|---|---|
| Without pathological findings | Borderline | Impaired | |
| Carbamazepine | 34 | 17 | 33 |
| Lamotrigine | 31 | 15 | 39 |
| Levetiracetam | 38 | 10 | 36 |
"Evaluation of Changes~Changes in the EpiTrack® Score were categorized as follows:~≥5 score points: Improved;~-3 to 4 score points: Unchanged;~≤-4 score points: Worsened" (NCT00438451)
Timeframe: week 58
| Intervention | participants (Number) | ||
|---|---|---|---|
| Improved | Unchanged | Worsened | |
| Carbamazepine | 16 | 56 | 8 |
| Lamotrigine | 15 | 53 | 13 |
| Levetiracetam | 15 | 61 | 6 |
3 reviews available for carbamazepine and Aging
| Article | Year |
|---|---|
Clinical pharmacokinetics of antiepileptic drugs in adults.
Topics: Adult; Aging; Anticonvulsants; Carbamazepine; Clonazepam; Diazepam; Disease; Ethosuximide; Female; H | 1980 |
[The effect of carbamazepine on the thyroid status of epilepsy patients (a review)].
Topics: Aging; Carbamazepine; Dose-Response Relationship, Drug; Epilepsy; Humans; Thyroid Gland; Thyroid Hor | 1993 |
Clinical pharmacokinetics of anticonvulsants.
Topics: Administration, Oral; Adult; Aged; Aging; Animals; Anticonvulsants; Carbamazepine; Child; Clonazepam | 1976 |
7 trials available for carbamazepine and Aging
| Article | Year |
|---|---|
New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine.
Topics: Aged; Aging; Amines; Anticonvulsants; Carbamazepine; Cerebral Infarction; Cyclohexanecarboxylic Acid | 2005 |
Differential effects of antiepileptic drugs on sexual function and hormones in men with epilepsy.
Topics: Adolescent; Adult; Age Factors; Aging; Anticonvulsants; Carbamazepine; Cross-Sectional Studies; Down | 2005 |
Factors influencing plasma concentrations of carbamazepine and carbamazepine-10,11-epoxide in epileptic children and adults.
Topics: Adolescent; Adult; Aging; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Chromatography, H | 1995 |
Influence of sex, age, weight, and carbamazepine dose on serum concentrations, concentration ratios, and level/dose ratios of carbamazepine and its metabolites.
Topics: Aging; Body Weight; Carbamazepine; Child; Child, Preschool; Dose-Response Relationship, Drug; Epilep | 1994 |
Standardisation of a self-report questionnaire for use in evaluating cognitive, affective and behavioural side-effects of anti-epileptic drug treatments.
Topics: Adolescent; Adult; Affect; Aging; Anticonvulsants; Behavior; Carbamazepine; Cognition Disorders; Dou | 1996 |
Event-related potentials (P300) and EEG activity in childhood partial epilepsy.
Topics: Adolescent; Aging; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Cognition; Electroenceph | 1997 |
The effects of age on carbamazepine pharmacokinetics and adverse effects.
Topics: Adult; Aged; Aging; Carbamazepine; Double-Blind Method; Female; Humans; Kinetics; Male; Psychomotor | 1986 |
37 other studies available for carbamazepine and Aging
| Article | Year |
|---|---|
Patterns of antiepileptic drug use among elderly patients with epilepsy: 2004-2015.
Topics: Aged; Aged, 80 and over; Aging; Anticonvulsants; Carbamazepine; Cross-Sectional Studies; Epilepsy; F | 2020 |
The impact of age on lamotrigine and oxcarbazepine kinetics: a historical cohort study.
Topics: Adult; Aged; Aging; Anticonvulsants; Carbamazepine; Cohort Studies; Dose-Response Relationship, Drug | 2013 |
Expression of UDP-Glucuronosyltransferase 1 (UGT1) and Glucuronidation Activity toward Endogenous Substances in Humanized UGT1 Mouse Brain.
Topics: Adult; Aging; Animals; Brain Chemistry; Carbamazepine; Estradiol; Female; Glucuronides; Humans; Isoe | 2015 |
Relationship between mono-hydroxy-carbazepine serum concentrations and adverse effects in patients on oxcarbazepine monotherapy.
Topics: Adolescent; Adult; Aged; Aging; Anticonvulsants; Carbamazepine; Child; Databases, Pharmaceutical; Dr | 2015 |
Risk factors for late-onset seizures related to cerebral contusions in adults with a moderate traumatic brain injury.
Topics: Adult; Aged; Aging; Anticonvulsants; Brain; Brain Injuries; Carbamazepine; Electroencephalography; F | 2011 |
Factors influencing carbamazepine pharmacokinetics in children and adults: population pharmacokinetic analysis.
Topics: Adult; Aging; Anticonvulsants; Carbamazepine; Child; Chromatography, High Pressure Liquid; Drug Inte | 2011 |
[Epilepsy in elderly].
Topics: Aged; Aged, 80 and over; Aging; Anticonvulsants; Carbamazepine; Electroencephalography; Epilepsies, | 2011 |
Acquired epileptic dysgraphia: a longitudinal study.
Topics: Aging; Agraphia; Anticonvulsants; Carbamazepine; Child; Electroencephalography; Epilepsy, Rolandic; | 2003 |
Phenobarbital pharmacokinetics in old age: a case-matched evaluation based on therapeutic drug monitoring data.
Topics: Adult; Age Distribution; Age Factors; Aged; Aged, 80 and over; Aging; Algorithms; Anticonvulsants; B | 2005 |
10-Hydroxycarbazepine serum concentration-to-oxcarbazepine dose ratio: influence of age and concomitant antiepileptic drugs.
Topics: Adult; Aging; Anticonvulsants; Carbamazepine; Chromatography, Liquid; Drug Administration Schedule; | 2005 |
Hyponatremia from oxcarbazepine and carbamazepine.
Topics: Adult; Age Factors; Aging; Anticonvulsants; Carbamazepine; Databases, Factual; Dose-Response Relatio | 2005 |
Population pharmacokinetic modelling of carbamazepine in epileptic elderly patients: implications for dosage.
Topics: Adult; Aged; Aging; Anticonvulsants; Bayes Theorem; Carbamazepine; Databases, Factual; Epilepsy; Fem | 2006 |
Factors affecting antiepileptic drug pharmacokinetics in community-dwelling elderly.
Topics: Absorption; Adult; Aged; Aged, 80 and over; Aging; Anticonvulsants; Biological Availability; Carbama | 2007 |
Carbamazepine and serum sodium levels.
Topics: Adolescent; Adult; Aged; Aging; Arginine Vasopressin; Carbamazepine; Child; Child, Preschool; Cyclic | 1984 |
Effects of carbamazepine and diphenylhydantoin on metrazol seizures during ontogenesis in rats.
Topics: Aging; Animals; Carbamazepine; Male; Pentylenetetrazole; Phenytoin; Rats; Rats, Inbred Strains; Seiz | 1983 |
A retrospective study on epileptic patients treated with carbamazepine: interaction between age and co-medication on the drug disposition.
Topics: Adolescent; Adult; Aged; Aging; Carbamazepine; Child; Child, Preschool; Drug Interactions; Epilepsy; | 1983 |
Carbamazepine plasma levels in children and adults: influence of age, dose, and associated therapy.
Topics: Adolescent; Aging; Carbamazepine; Child; Child, Preschool; Drug Therapy, Combination; Epilepsy; Fema | 1980 |
Factors influencing simultaneous concentrations of carbamazepine and its epoxide in plasma.
Topics: Adolescent; Adult; Aging; Anticonvulsants; Biotransformation; Carbamazepine; Drug Interactions; Fema | 1981 |
The formation of carbamazepine epoxide by rat liver microsomes: an investigation of the biphasic kinetic profile.
Topics: Aging; Animals; Carbamazepine; Kinetics; Male; Methylcholanthrene; Microsomes, Liver; Phenobarbital; | 1981 |
The influence of polytherapy on the relationships between serum carbamazepine and its metabolites in epileptic children.
Topics: Aging; Anticonvulsants; Body Weight; Carbamazepine; Child; Chromatography, High Pressure Liquid; Dru | 1994 |
Differential action of phenytoin and carbamazepine on cortical interhemispheric responses in young but not in adult rats.
Topics: Aging; Analysis of Variance; Animals; Carbamazepine; Electric Stimulation; Epilepsy, Tonic-Clonic; M | 1993 |
Potential drug--drug interactions in 5,125 mostly elderly out-patients in Gothenburg, Sweden.
Topics: Aged; Aged, 80 and over; Aging; Carbamazepine; Cohort Studies; Digoxin; Drug Interactions; Drug Pres | 1995 |
Detection of carbamazepine-induced changes in valproic acid relative clearance in man by simple pharmacokinetic screening.
Topics: Adolescent; Adult; Aging; Anticonvulsants; Body Weight; Carbamazepine; Child; Child, Preschool; Drug | 1997 |
[Partial seizures during the course in patients with absence epilepsy].
Topics: Adolescent; Adult; Aging; Carbamazepine; Central Nervous System; Child; Electroencephalography; Epil | 1999 |
Effects of pharmacological and nonpharmacological treatments on thyroid hormone metabolism and concentrations in rat brain.
Topics: Aging; Animals; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Brain; Brain Chemistry | 2000 |
Factors contributing to carbamazepine-macrolide interactions.
Topics: Adolescent; Adult; Aged; Aging; Anti-Bacterial Agents; Anticonvulsants; Body Weight; Carbamazepine; | 2002 |
Carbamazepine pharmacokinetics in young, adult and pregnant rats. Relation to pharmacological effects.
Topics: Aging; Animals; Carbamazepine; Electroshock; Female; Kinetics; Male; Maternal-Fetal Exchange; Pentob | 1976 |
Clinical pharmacokinetics in infants and children.
Topics: Aging; Body Water; Carbamazepine; Child; Child, Preschool; Clindamycin; Dextropropoxyphene; Diazoxid | 1976 |
Distribution of carbamazepine and its epoxide in blood compartments in adolescent and adult epileptic patients.
Topics: Adolescent; Adult; Aged; Aging; Blood Proteins; Carbamazepine; Chromatography, High Pressure Liquid; | 1992 |
A within-subject analysis of carbamazepine disposition related to development in children with epilepsy.
Topics: Adolescent; Aging; Carbamazepine; Child; Child Development; Child, Preschool; Dose-Response Relation | 1992 |
Age dependency of the susceptibility of rats to aminooxyacetic acid seizures.
Topics: Aging; Aminooxyacetic Acid; Animals; Anticonvulsants; Body Temperature; Brain; Carbamazepine; Clonaz | 1992 |
The influence of age on the pharmacokinetics of the antiepileptic agent oxcarbazepine.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aging; Analysis of Variance; Anticonvulsants; Carbamazep | 1991 |
Carbamazepine age-dose ratio relationship in children.
Topics: Adolescent; Adult; Aging; Carbamazepine; Child; Child, Preschool; Dose-Response Relationship, Drug; | 1991 |
Analysis of the factors influencing anti-epileptic drug concentrations--carbamazepine.
Topics: Aging; Body Weight; Carbamazepine; Dose-Response Relationship, Drug; Drug Interactions; Female; Huma | 1990 |
Analysis of the factors influencing anti-epileptic drug concentrations--valproic acid.
Topics: Adolescent; Adult; Aging; Aspartate Aminotransferases; Body Weight; Carbamazepine; Dose-Response Rel | 1990 |
Effect of carbamazepine on cortical interhemispheric responses in adult and young rats.
Topics: Aging; Animals; Anticonvulsants; Carbamazepine; Cerebral Cortex; Functional Laterality; Male; Rats | 1989 |
Effects of carbamazepine and phenobarbital on kainic acid-induced model of psychomotor seizures during ontogenesis in the rat.
Topics: Aging; Animals; Carbamazepine; Dose-Response Relationship, Drug; Kainic Acid; Male; Phenobarbital; R | 1989 |